Stock Price & Analysis

Based on the provided data and recent market activity, DNA stock is showing mixed signals with a 6.18% gain in regular trading but -2.12% decline in post-market on January 17, 2025, suggesting cautious trading around the current $10.70 level until clearer directional momentum emerges.

Based on the provided data and context, here's a concise 3-sentence price prediction for DNA stock in 2025:

DNA stock is expected to reach $13.16 by mid-2025, supported by its recent strategic partnership with Carnegie Mellon University for bioelectronic cell-based devices and growing momentum in the biotech sector. The company's focus on cost reduction and restructuring efforts, combined with its expanding capabilities in mammalian cell engineering, positions it well for growth despite current market volatility. However, investors should note that achieving this target depends heavily on the successful execution of their cost-saving initiatives and the broader market's reception to their biotech innovations, as indicated by recent analyst coverage.

The S1 support level for DNA Stock is $8.94 ,The R1 resistant level for DNA Stock is $13.38.

As of the end of day on 2025-01-24, the price of DNA Stock was $12.9.

The target price for DNA Stock according to analyst rating is 8.67, with the highest price target at 10.00 and the lowest at 6.00. Analysts have a Hold rating on DNA Stock overall.

The market cap of DNA is $698.4M.

Based on the provided data and recent market developments, here's a concise analysis of DNA's valuation:

Financial Performance DNA shows concerning financial metrics with significant net losses in recent quarters, though improving from -$217M in Q2 to -$56M in Q3 2024. Revenue growth is positive, increasing from $37.9M to $89M between Q1-Q3 2024.

Valuation Metrics The company trades at:

• Price-to-Sales (P/S): 1.9x (Q3 2024)
• Price-to-Book (P/B): 0.54x (Q3 2024)
• No meaningful P/E ratio due to negative earnings

Recent Developments The company recently secured a $9.4M contract with Carnegie Mellon University for developing bioelectronic cell-based devices, demonstrating continued innovation but relatively small contract size compared to losses.

Market Position DNA operates in a growing market with DNA sequencing industry projected to reach $34.8B by 2029 at 18.6% CAGR, but faces significant competition and profitability challenges.

Conclusion DNA appears overvalued considering:

• Persistent large operating losses despite revenue growth
• Negative profit margins (-63.34% in Q3 2024)
• Limited cash flow generation relative to market expectations
• Mixed analyst ratings with significant downside targets
• High cash burn rate despite recent operational improvements

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.

Based on the provided data and market analysis, here is the price prediction for DNA (Ginkgo Bioworks) stock by 2030:

Ginkgo Bioworks (DNA) stock is projected to reach $25-30 by 2030, driven by its dominant position in synthetic biology and recent strategic partnerships, including a $9.4 million contract with Carnegie Mellon University for developing bioelectronic cell-based devices. The company's current technical indicators showing RSI at 56.50 and positive MACD of 0.19 suggest a healthy upward momentum, while its 80% market share in the U.S. exome market demonstrates strong competitive positioning.

DNA has a total of 1218 employees.